Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?

Table 2 Reduction of daily ‘OFF’ time with continuous subcutaneous apomorphine infusion treatment

Study	Number of participants	Average follow-up duration (months)	Reduction of daily ‘OFF’ time (%)
Stibe et al. [68]	11	8	62
Chaudhuri et al. [69]	7	11	85
Frankel et al. [70]	25	22	55
Pollak et al. [71]	9	10	67
Hughes et al. [72] ±	22	36	59
Stocchi et al. [73]	10	12	58
Poewe et al. [74]	18	20	58
Kreczy-Kleedorfer et al. [75]	14	26	77
Gancher et al. [76]	6	3	58
Colzi et al. [77] ±	19	35	72
Pietz et al. [78] ±	25	44	50
Wenning et al. [79] ±	16	57	55
Kanovsky et al. [80]	12	24	80
Manson et al. [81] ±	64	34	49
Di Rosa et al. [82]	12	12	40
Morgante et al. [83]	12	24	60
Katzenschlager et al. [84]	12	6	38
De Gaspari et al. [85]	13	12	51
Garcia-Ruiz et al. [86]	82	20	80
Martinez-Martin et al. [87]	17	6	65
Antonini et al. [88]	12	60	49
Drapier et al. [89]	23	12	36
Borgemeester et al. [90]	45	26	45
Sesar et al. [91]	230	26	78
Sesar et al. [92]*	18	16	74
Papuc et al. [93] ±	9	24	86
Isaacson et al. [94]	99	3	47
Katzenschlager et al. [60]	84	52	53
Weighted average improvement in OFF time**			62.4

Data from open-label studies assessing the efficacy of continuous subcutaneous apomorphine infusion (CSAI) in reducing ‘OFF’ time in the treatment of patients with advanced Parkinson’s disease. Only studies with reported reduction of daily ‘OFF’ time were included
±Studies in which CSAI monotherapy was achieved in the whole cohort or in a sub-group of patients
*Only the cohort before deep brain stimulation has been included
**Weighted for participant number per study

ISSN: 2047-9158